Latest news
Scientific events
Inserm osteoarthritis research network
Peripheral and spine osteoarthritis: from pathophysiology to transformative therapeutics
1st NetwOArk Autumn School
November 23rd, 2023, Buffon Amphitheatre - 15 rue Hélène Brion, Paris 13, France
Invitation and Call for oral presentations
The Inserm and ITMO PMN are happy to announce the First OsteoArthritis research Network (NetwOArk) Autumn School to be held on November 23rd, 2023 in the Buffon Amphitheatre (15 rue Hélène Brion - Paris 13). The aim of this meeting is to facilitate interactions between senior and junior researchers working in the field of osteoarthritis.
The Inserm osteoarthritis research network (NetwOArk) aims to bring together all the scientific actors involved in research on osteoarthritis, in order to federate and promote the emergence of high-level scientific work in this field. NetwOArk is supported by Inserm and the life science Institute Pathophysiology Metabolism Nutrition (IT PMN).
Coordinators: Jérôme Guicheux (INSERM U1229, Nantes Université), Francis Berenbaum (INSERM U938, Sorbonne Université).
More informations | Abstract Submission |
Program | Registration |
Additive Manufacturing for Health workshop
The 2nd Edition of the Additive Manufacturing for Health workshop (www.amh-workshop.com) will take place on March 21-22, 2024, in Nantes, France.
RMeS in the spotlight
Article de Catherine Le Visage sur l'arthrose paru dans Le Figaro Santé
(https://www.lefigaro.fr/sciences/arthrose-l-espoir-des-cellules-souches-la-necessite-de-la-prevention-20230625)
La Science, CQFD
Quelles sont les pistes thérapeutiques à l’étude pour traiter l'arthrose ?
Claire Vinatier Enseignante-chercheuse à l’Université de Nantes, au laboratoire Hermes, de médecine régénératrice et squelette.
Francis Berenbaum Chef de service de rhumatologie au CHU Saint-Antoine de l’APHP.
Ecouter l'émission radio : https://www.radiofrance.fr/franceculture/podcasts/la-science-cqfd/mignonne-allons-voir-si-l-arthrose-8569072
Arthrose : des cellules souches encapsulées pour protéger l’articulation
Communication Grand Public
Lien vers l'article
Announcements
PEPR CARN
As part of France 2030's acceleration strategies, one action is dedicated to the funding of translational research through the Priority Research Programs and Equipment (PEPR). The REJOINT team is delighted to announce a PEPR funding within the Biotherapies and Bioproduction of Innovative Therapies (BBiT) program. UMR 7057-MSC (F. Gazeau) and UMR 1229-RMeS (J. Guicheux) will co-lead the CARN project (3.5 M€) dedicated to the development of biotherapies based on the local delivery of therapeutic RNA by functionalized hybrid extracellular vesicles (EVs) for joint diseases. This project will also involve the UMR 8612 (E. Fattal), UMR 5253 (M. Morille), UMS 55-ART ARNm (C. Pichon) and UMR 1183-IRMB (C. Jorgensen).
CARN is a 4 year-project with a kick-off official date August 31, 2023.
It is organized into 5 workpackages (WP) as follows :
-WP1. Identification and validation of therapeutic RNAs for knee and intervertebral disc osteoarthritis. Leaders Claire Vinatier & Danièle Noel
-WP2. High yield production of mesenchymal stromal cells-derived EVs and RNAs and per-production hybridization of EVs and RNA. Leaders: Chantal Pichon & Florence Gazeau
-WP3. Engineering, optimization and functionalization of hybrid EVs. Leaders: Elias Fattal & Marie Morille
-WP4. Efficacy evaluation of hybrid EVs in vitro and in the zebrafish model. Leaders: Farida Djouad & Jerome Guicheux
-WP5. Pre-clinical studies in small (mice) and large (sheep) animal models of knee and disc osteoarthritis. Leaders: Catherine Le Visage & Christian Jorgensen
By proposing functionalized hybrid EVs decorated with recognition elements and loaded with disease-modifying therapeutic RNAs, CARN will open new therapeutic opportunities for hybrid EVs in the treatment of chronic inflammatory joint diseases.
Fondation d’entreprise Grand Ouest – Prix encouragement recherche – Projet ANDROID2
The REGOS team of the INSERM U1229-RMeS laboratory is pleased to announce the recent award to Guillaume MABILLEAU (INSERM U1229, RMeS) from the Fondation d’entreprise Grand Ouest. This award will help to pursue the development of dual GIP/GLP-2 analogues for the prevention and treatment of bone fragility.
Fondation Arthritis - SPOTT project
The REJOINT team is pleased to announce the funding of the "SPatial multi-Omic profiling of synovial tissue to uncover novel Therapeutic Targets in osteoarthritis (SPOTT)" project, coordinated by Marie-Astrid Boutet (StratOA group).
The SPOTT project aims to:
(i) Analyse the spatial multi-omic profile of OA synovial tissue to refine patients’ stratification,
(ii) Validate the expression of identified cellular or molecular targets for the future development of innovative therapeutic strategies.
SPOTT is an emergent project, which implements for the first-time breakthrough conceptual and technological approaches and will facilitate the development of larger impactful projects in the context of OA and beyond with a huge potential to accelerate the translation of basic scientific observations into patients’ benefits.
ANR PVNS
Pigmented villonodular synovitis (PVNS) is a rare joint disease characterized by a benign proliferative lesion arising from synovia that results in a secondary inflammatory joint response, pain, and destruction. The PVNS project, coordinated by Benoit Le Goff and Frédéric Blanchard (RMeS, T-Syno group) in collaboration with Fabienne Coury (INSERM UMR1033, Lyon) and Jérôme Avouac (INSERM U1016 Paris), has 3 main aims:
- To better understand PVNS pathophysiology using high throughput technologies in a cohort of PVNS patients and identify new therapeutic targets
- To set up an in vitro platform to better understand the crosstalk between cells and test new drugs and therapeutic targets on cells and tissues from PVNS patients
- To use and further develop original mouse models of PVNS to test drugs or new therapeutic targets, combined with a local delivery system, for treating PVNS patients
Funding of a new project by the Fondation de l'Avenir
The objective of this project, coordinated by Benoit Le Goff and Frédéric Blanchard (RMeS, T-Syno group), is to provide proof of principle that the local delivery of molecules interacting with the CSF1 pathway is feasible and effective in in vitro and in vivo models of Pigmented villonodular synovitis (PVNS). We will test a panel of therapeutic molecules on PVNS cells and explants in vitro and measure their impact on cell viability. The active molecules will then be studied in a mouse model of synovial tissue xenograft from patients with PVNS.
TARGET-OA
The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the “TARGET-OA: targeting the chondrocyte-derived CXCL12/endothelial cell CXCR4 axis in osteoarthritis” collaborative research project by the 2023 ANR Call. The ARGET-OA project is coordinated by Xavier Houard (INSERM UMRs 938 Centre de Recherche Saint Antoine, Paris) in collaboration with Marie-Hélène Lafage-Proust (INSERM U1059 SAINBIOSE, St Etienne) and Claire Vinatier (INSERM U1229-RMeS, AGE-OA group). In the TARGET-OA project, we propose that the CXCL12 / CXCR4 axis has a crucial role in the dialogue between hypertrophic chondrocytes and endothelial cells in OA. Our objectives are to define the role of this axis in pathological communication between chondrocytes and endothelial cells and to demonstrate that its targeting has a clinical interest in the treatment of OA.
ANR DISPHPE
The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the DISPHPE collaborative research project by the 2022 ANR Call on Translational Research in Health. In the DISPHPE project: “Comprehensive study of DISP1 gene variants to reach genotype-phenotype relationships of congenital anterior midline defects” coordinated by Valérie Dupé (IGDR, Rennes), Anne Camus (BIODIV Group, INSERM U1229, RMeS) will develop human induced pluripotent stem cells-based experimental models to investigate key molecular and functional aspects of developmental disorders arising during embryogenesis and related to the signaling role of the notochord.
L’exploration du rôle de la senescence cellulaire dans la maladie discale soutenue par la SFR
Dans le cadre de sa subvention aux projets individuels de recherche, la Société Française de Rhumatologie (SFR) a attribué une bourse [de 20000€] au projet « MoSCITO » porté par Romain GUIHO (La MOdulation de la Sénescence Cellulaire comme Innovation Thérapeutique dans la discOpathie dégénérative). En plus de faire progresser considérablement la caractérisation des cellules sénescentes dans le disque intervertébral, le projet MoSCITO a l'ambition de valider une nouvelle approche thérapeutique, ouvrant la voie à des progrès concrets et considérables dans la gestion clinique de la maladie discale.
A new collaborative project funded by the SFR: Characterization and new therapeutic options for pigmented villonodular synovitis (PVNS). It will be coordinated by Benoit Le Goff and Frédéric Blanchard in collaboration with Fabienne Coury (INSERM UMR1033, Lyon) and Jérôme Avouac (INSERM U1016 Paris). This project aims to
- set up a multicentric biocollection of patients with PVNS;
- explore the mechanisms leading to the development of synovitis (inflammation, genetic mutations, vascular compartment) using high-throughput technologies
- evaluate in vitro the biological activity of several drugs, in particular those targeting the CSF1 pathway, on tissues /cells from PVNS patients.
Bourse novartis DREAMER
Dr Christelle DARRIEUTORT-LAFFITESujet de recherche : Etude de la cicatrisation d’un défect tendineux du supra-épineux chez la souris : analyse transcriptomique des populations cellulaires impliquées
Description du projet :
Résumé : Bien que les tendinopathies représentent une problématique médicale fréquente, les options thérapeutiques restent peu nombreuses. Le tendon ayant une faible vascularisation et une faible cellularité, ses capacités naturelles de régénération/réparation sont faibles. Ce contexte, associé à nos connaissances limitées de la biologie des cellules du tendon et de la régulation de la ténogenèse, font du traitement des tendinopathies un réel challenge médical et scientifique. Des données récentes issues du Single-cell RNA-Sequencing démontrent la présence de populations de ténocytes hétérogènes au sein du tendon sain. Aucune donnée n’est disponible sur les changements au sein de ces populations cellulaires après une lésion tendineuse.
Objectifs : Etudier par Single-Cell RNA-Sequencing les populations cellulaires présentes au sein du tendon lors des différentes phases de la cicatrisation après une lésion partielle induite chirurgicalement au niveau du supra-épineux. Les échantillons seront recueillis à différents temps : en phase inflammatoire (J7), à la phase de prolifération (J21) et lors de la phase de remodelage (J42). Les échantillons seront également étudiés en histologie et immunohistochimie aux différents temps expérimentaux.
ANR NEMESIS
Low back pain (LBP) has been associated with intervertebral disc (IVD) degeneration. The recent identification of the microRNA (miR) role in IVD biology and degeneration allows considering miRs as new targets, but also as new potential therapeutic agents. The development of in vivo delivery systems, particularly miR-loaded nanocarriers, has thus been an area of active research. As a whole, the objectives of the NEMESIS project are (i) to set-up the formulation and characterization of miR-loaded nanocarriers, (ii) to implement potency assays and assess the interactions of miR-loaded nanocarriers with target cells in vitro and in an ex vivo whole IVD culture system and (iii) to establish the proof of concept of miR-loaded nanocarriers as a new therapeutic option in the management of DDD in an ovine preclinical model and in canine clinical trials. The NEMESIS project is based on an inter- and multi-disciplinary consortium composed of J. Clouet (scientific leader, RMeS lab), M. Fusellier (scientific co-leader, RMeS lab and ONIRIS) and Elise Lepeltier (scientific partner, MINT lab, Angers).ATIP-Avenir SAMBA
Mandibular atrophy induced by the lack of a proper dentition is a major medical and socio-economic burden worldwide: the remaining bone volume is not sufficient to place dental implants to restore physiological functions. Although bone augmentation procedures exist, they are often heavy and complex, costly, and not deprived of risks (e.g., autologous bone graft). The ATIP-Avenir SAMBA program (INSERM/CNRS) will allow for the creation of a new group in RMeS Lab to tackle this issue, by developing among others 3D-printed patient specific biomimetic scaffolds for bone regeneration.
MiRbone By SFR
Age-related bone loss is a major medical and socio-economic problem worldwide. Many microRNAs are involved in bone homeostasis and may play a role in the development of osteoporosis. In the miRbone project funded by the SFR, Valérie Geoffroy and Frédéric Jehan (REGOS team) propose to dissect, using an "omic" approach, the mode of regulation of bone metabolism by one of these microRNAs, miR-199a2, whose significant effect in bone mass accrual has been demonstrated, with the aim of identifying new therapeutic targets to improve the management of bone loss in elderly patients.
ANR-DYNAM-OA
Osteoarthritis (OA) has no cure to date. To identify new therapeutic targets and screen drugs, researchers need in vitro OA joint models that are biologically relevant and reproducible. Bioprinting-assisted OA modeling is a promising avenue of research, yet bioprinting tools are limited. With the DYNAM-OA project, Vianney Delplace (BIOMAX group) propose to develop a new ultra-modular bioprinting toolbox, including a universal bioink platform and a strategy to produce gradient constructs, and apply these tools for the design of the first generation of bioprinted OA joint models.
ANR-COBIOSTEM
Traumatic brain injuries (TBI) are a critical public health and socio-economic problem throughout the world, with limited treatment options available. Cell transplantation offers a viable treatment strategy for patients with TBI, but transplanted neurons alone often rapidly die and fail to integrate brain tissue, leading to limited recovery. In the COBIOSTEM project, led by Afsaneh Gaillard (INSERM U1084 - LNEC), Vianney Delplace (BIOMAX group) will design a new generation of injectable hydrogels to improve the survival rate of transplanted cortical neurons, and enhance the long-term efficacy of cell transplantation to the brain.
International Research Project (IRP) Inserm (2022) GLYCODISC
The goal of the GLYCODISC projet is to consolidate a cooperating relationship between France (PI: Catherine LE VISAGE, Inserm) and Hong Kong (PI: Barbara CHAN, The University of Hong Kong (HKU)), in the field of regenerative medicine for intervertebral disc disease and low back pain.
The funding (75 000 euros, duration 5 years) aims to primarily contribute to mobility and organization of meetings. The ultimate outcome of the program is to lay the foundation for a large-scale international collaborative project with scientists from both countries.
ANR SmartIEs (2022)
The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the SmartIEs proposal as an ANR collaborative research project.
SmartIEs will be coordinated by Sylvia COLLIEC-JOUAULT (IFREMER) and will be carried out in collaboration with Stéphane CUENOT (Institut des Matériaux) and Catherine Le Visage (INSERM U1229, RMeS). The SmartIEs project will explore a cell-free strategy through conception of a smart hydrogel scaffold highly efficient to recruit regenerative progenitor cells and to stimulate their differentiation into appropriate cell lineages able to regenerate both cartilage and subchondral bone.
Publications
Development of a DNA damage-induced senescence model in osteoarthritic chondrocytes
Mélina Georget, Anaïs Defois, Romain Guiho, Nina Bon, Sophie Allain, Cécile Boyer, Boris Halgand, Denis Waast, Gaël Grimandi, Alban Fouasson-Chailloux, Jérôme Guicheux, Claire Vinatier
PMID: 33227437 PMCID: PMC7925350 DOI: 10.1016/j.joca.2020.11.004
Abstract and more
Williams R.J., Laagland L.T., Bach F.C., Ward L., Chan W., Tam V., Medzikovic A., Basatvat S., Paillat L., Vedrenne N.,
Snuggs J.W., Poramba-Liyanage D.W., Hoyland J.A., Chan D., Camus A., Richardson S.M., Tryfonidou M.A., Le Maitre C.L. (2023). Recommendations for intervertebral disc notochordal cell investigation: From isolation to characterization. JOR Spine 1272:1-22. DOI: 10.1002/jsp2.1272.
Abstract and more
Anais Defois , Nina Bon, Alexandre Charpentier , Melina Georget, Nicolas Gaigeard, Frederic Blanchard, Antoine Hamel, Denis Waast, Jean Armengaud, Ophelie Renoult, Claire Pecqueur, Yves Maugars, Marie-Astrid Boutet , Jerome Guicheux, Claire Vinatier
Cell Communication and signaling
Abstract and more
PPARβ/δ-Interfering Peptide Enhanced Mesenchymal Stromal Cell Immunoregulatory Properties
Gautier Tejedor,Prisca Boisguerin, Éric Vivès, Christian Jorgensen, Jérôme Guicheux, Claire Vinatier, Claire Gondeau, and Farida Djouad
Stem Cells International
Runser J-Y, Fneich F, Senger B, Weiss P, Jierry L, Schaaf P
Journal of Colloid and Interface Science, 2022 Nov 22
Abstract and more
Freuchet A, Salama A, Bézie S, Tesson L, Rémy S, Humeau R, Règue H, Sérazin C, Flippe L, Peterson P, Vimond N, Usal C, Ménoret S, Heslan JM, Duteille F, Blanchard F, Giral M, Colonna M, Anegon I, Guillonneau C.
Clin Transl Med. 2022 Aug;12(8):e988. doi: 10.1002/ctm2.988.
Abstract and more
Bone characteristics in condylar hyperplasia of the temporomandibular joint: a microcomputed tomography, histology, and Raman microspectrometry study.
Kün-Darbois JD, Bertin H, Mouallem G, Corre P, Delabarde T, Chappard D.
Int J Oral Maxillofac Surg. 2022 Sep 27
Abstract and more
Update on contribution of hip labral tears to hip pain: a narrative review.
Berthelot JM, Brulefert K, Arnolfo P, Le Goff B, Darrieutort-Laffite C.
Joint Bone Spine. 2022 Sep 20
Abstract and more
Florimond
M, Minic S, Sharpe P, Chaussain C, Renard E, Boukpessi T.
Int J Mol Sci. 2022 Sep 13
Abstract and more
New members
PhD defense & HDR
Soutenance de thèse Mathilde Ambrosino, le 05/12/2023
"Injection intra-articulaire de cellules souches mésenchymateuses associées à un hydrogel boronique cytoprotecteur: évaluation dans un modèle d'arthrose chez le lapin»"
Flyer de l'unité
Devstem
Florian BERGER, INSERM UMR1064 - CR2TI - Team 2 , nous présentera les résultats de son projet de thèse sur le sujet "Sperm epigenetic programming during Xenopus laevis spermatogenesis".
Mots Clés : Human preimplantation - In Vitro Fertilization - Signaling pathway.
Contact : anne.camus@univ-nantes.fr
Création du Club Macrophage Grand Ouest
Le club Macrophage Grand Ouest regroupe des équipes de recherche de Nantes, Angers, Rennes et Tours. Il a notamment pour but de favoriser les échanges scientifiques et techniques entre les équipes travaillant sur les macrophages et autres phagocytes mononucléés, d'aider les collaborations locales, et de donner l'opportunité aux jeunes de présenter leurs travaux de recherche.
La journée annuelle du Club Macrophage & co du Grand Ouest aura lieu le mercredi 4 octobre 2023 à Rennes.
N'hésitez pas à consulter le programme prévisionnel et à vous inscrire sur notre site: https://macrophage-grandouest.fr/
La date limite d'inscription est fixée au vendredi 15 septembre à 12h.